Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
NYSE:RFL

Rafael 6/14/2024 Earnings Report

Rafael logo
$1.27 0.00 (-0.16%)
Closing price 05/6/2026 03:58 PM Eastern
Extended Trading
$1.27 +0.00 (+0.16%)
As of 05/6/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Rafael EPS Results

Actual EPS
-$1.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Rafael Revenue Results

Actual Revenue
$0.34 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rafael Announcement Details

Quarter
Date
6/14/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Rafael's Q3 2026 earnings is estimated for Wednesday, June 10, 2026, based on past reporting schedules, with a conference call scheduled on Friday, June 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Rafael Earnings Headlines

Rafael Holdings Insider Ups Holding By 1,810% During Year
April 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rafael-holdings-insider-ups-holding-142622929.html
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
April 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-improve-myelination-in-apoe4-positive-alzheimer-s-disease-1036048049
$30 stock to buy before Starlink goes public (WATCH NOW!)
A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.tc pixel
 |  Paradigm Press (Ad)
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278798/0/en/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-improve-myelination-in-apoe4-positive-alzheimer-s-disease.html
Rafael Holdings Inc. Wt
April 4, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/rfl.wt/company-people
Rafael Holdings, Inc.: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
March 17, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67960421-rafael-holdings-inc-rafael-holdings-reports-second-quarter-fiscal-2026-financial-results-399.htm
See More Rafael Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rafael? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rafael and other key companies, straight to your email.

About Rafael

Rafael (NYSE:RFL) primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

View Rafael Profile
Earnings Tools